Bulk Pharmaceutical API Sources for NAMZARIC

Bulk Pharmaceutical API Sources for NAMZARIC

Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical		2023-05-11B3894

NAMZARIC Bulk API Sourcing: A Patent and Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and potential bulk active pharmaceutical ingredient (API) sources for NAMZARIC, a fixed-dose combination of NAMENDA XR (memantine HCl) and DONEPEZIL HCl. The analysis focuses on patent expiry, key manufacturers, and strategic considerations for API sourcing.

What is NAMZARIC and its Therapeutic Use?

NAMZARIC is a prescription medication approved for the treatment of moderate to severe dementia of the Alzheimer's type. It combines memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. The dual mechanism of action targets different pathways involved in Alzheimer's disease pathology.

NAMZARIC's Active Pharmaceutical Ingredients (APIs)

The two APIs constituting NAMZARIC are:

• Memantine Hydrochloride: A low-to-moderate affinity uncompetitive antagonist of NMDA receptors.
• Donepezil Hydrochloride: A reversible inhibitor of acetylcholinesterase.

Patent Landscape for NAMZARIC

The patent protection for NAMZARIC and its constituent APIs is critical for understanding market exclusivity and potential for generic entry.

Memantine Hydrochloride Patents

Memantine hydrochloride has a long history of patent protection. The original patent for memantine (US Patent 3,962,427) was filed in the United States on June 24, 1964, and issued on June 7, 1976. While this foundational patent has long expired, subsequent patents have focused on:

• Formulations: Improved or extended-release formulations.
• Methods of Treatment: Specific uses or patient populations.
• Polymorphs: Crystalline forms of memantine hydrochloride.

A key patent related to extended-release formulations of memantine is US Patent 8,187,930, filed by Merz Pharma GmbH & Co. KGaA. This patent covers extended-release dosage forms of memantine hydrochloride. The expiry date for this patent, considering its last full term extension and potential patent term adjustments, is a critical factor for generic manufacturers seeking to enter the market with memantine-containing products. According to patent filings and publicly available information, the effective expiry of the core extended-release formulation patents for memantine has passed or is imminent in major markets, allowing for generic competition.

Donepezil Hydrochloride Patents

Donepezil hydrochloride, marketed under brand names like Aricept, has also undergone extensive patent protection. The original patents for donepezil were filed by Eisai Co., Ltd. and Pfizer Inc. US Patent 4,895,952, covering donepezil and its salts, was filed on October 26, 1987, and issued on January 23, 1990. Similar to memantine, subsequent patents have addressed various aspects, including:

• Specific Salt Forms: Different crystalline forms or salts of donepezil.
• Dosage Forms: Extended-release, orally disintegrating tablets, etc.
• Manufacturing Processes: Novel synthetic routes.

The primary patents for the immediate-release formulation of donepezil have expired. For instance, US Patent 5,604,213, related to a method for preparing a donepezil salt, issued in 1997. Extended-release formulations of donepezil have also seen their patent exclusivity periods expire or approach expiry. Generic manufacturers have been producing donepezil HCl for several years.

NAMZARIC Specific Patents

NAMZARIC itself, as a fixed-dose combination, is covered by its own set of patents. These patents typically claim:

• The Combination Itself: The specific combination of memantine HCl and donepezil HCl in a single dosage form.
• Dosage Regimens: Specific dosing schedules or titration protocols.
• Manufacturing Methods for the Combination Product: Processes for creating the fixed-dose formulation.

For example, US Patent 8,669,255, assigned to Axovant Sciences GmbH, covers methods of treating Alzheimer's disease using a combination of memantine and donepezil. The expiry of these specific combination patents is crucial for the commercialization of generic NAMZARIC. Given the product's launch, these patents were likely granted in the years preceding its market entry. The expiry of these patents will directly impact the timeline for generic availability of the NAMZARIC combination product. The projected expiry of key patents for the NAMZARIC combination product in major markets is generally around the mid-to-late 2020s, though this can vary due to patent litigation and extensions.

Bulk API Manufacturers: Memantine Hydrochloride

Memantine hydrochloride API is produced by a range of global manufacturers. The market is characterized by both established pharmaceutical ingredient suppliers and emerging generic API producers.

Key Manufacturers and Their Capabilities

• Merz Pharma GmbH & Co. KGaA: As the originator, Merz likely has internal API manufacturing capabilities or closely managed contract manufacturing organizations (CMOs). Their focus is on quality and regulatory compliance for their branded product.
• Chinese API Manufacturers: China is a significant global supplier of pharmaceutical APIs. Numerous companies in China specialize in memantine HCl, including:
  • Hubei Biocause Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Nanjing Union Pharmaceutical Factory. These manufacturers often offer competitive pricing and have scaled production capabilities, adhering to GMP (Good Manufacturing Practice) standards.
• Indian API Manufacturers: India also hosts a robust API manufacturing sector with expertise in generic APIs. Notable players include:
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Laurus Labs. Indian manufacturers are known for their strong regulatory track records and cost-effectiveness.
• European API Manufacturers: While less dominant than Asian manufacturers in sheer volume, some European companies also produce memantine HCl. These are often smaller, specialized API producers or CMOs catering to specific quality requirements.

Quality and Regulatory Considerations for Memantine HCl

When sourcing memantine HCl API, it is imperative to assess:

• GMP Compliance: Manufacturers must operate under current Good Manufacturing Practices (cGMP).
• DMF Filings: Drug Master Files (DMFs) submitted to regulatory agencies (e.g., FDA, EMA) provide detailed information about the API manufacturing process, quality control, and specifications.
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines is standard.
• Impurity Profiling: Strict control and characterization of impurities are critical, especially for APIs used in fixed-dose combinations.
• Supply Chain Security: Robust measures to prevent counterfeiting and ensure product integrity.

Bulk API Manufacturers: Donepezil Hydrochloride

Donepezil hydrochloride API is widely available from multiple manufacturers globally, reflecting its status as a mature generic drug.

Key Manufacturers and Their Capabilities

• Eisai Co., Ltd. and Pfizer Inc.: The originators may maintain some API production or have specific supply agreements.
• Indian API Manufacturers: India is a primary source for donepezil HCl API. Many of the same large Indian pharmaceutical companies that produce memantine HCl also manufacture donepezil HCl, including:
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Divi's Laboratories Limited. These companies offer high-volume production and competitive pricing.
• Chinese API Manufacturers: Chinese manufacturers are also significant contributors to the global donepezil HCl supply. Examples include:
  • Zhejiang NHU Co., Ltd.
  • Jiangsu Haosen Pharmaceutical Co., Ltd. They provide cost-effective options and have established export channels.
• Contract Manufacturing Organizations (CMOs): Numerous CMOs globally can produce donepezil HCl API under contract for pharmaceutical companies, offering flexibility in production scale and specifications.

Quality and Regulatory Considerations for Donepezil HCl

Similar to memantine HCl, sourcing donepezil HCl requires attention to:

• cGMP Certification: Essential for all API manufacturers.
• Regulatory Filings: Active DMFs or Certificates of Suitability (CEPs) from relevant authorities.
• Quality Control: Rigorous testing for identity, purity, assay, and residual solvents.
• Polymorph Control: For donepezil, specific polymorphic forms can impact bioavailability and stability. Manufacturers must demonstrate consistent production of the desired polymorph.
• Supply Chain Traceability: Ensuring the API's origin and movement are reliably tracked.

Sourcing Strategies for NAMZARIC API

For companies looking to develop or market generic versions of NAMZARIC, or to secure API for other related applications, a strategic sourcing approach is essential.

Dual Sourcing Strategy

• Mitigation of Risk: Engaging with at least two qualified API suppliers for each API (memantine HCl and donepezil HCl) is crucial for supply chain resilience. This mitigates risks associated with single-source reliance, such as production issues, regulatory disruptions, or geopolitical instability.
• Negotiation Leverage: Having multiple suppliers enhances negotiation power for pricing and contract terms.

Supplier Qualification Process

• Audits: Conduct thorough on-site audits of potential suppliers' manufacturing facilities to verify cGMP compliance, quality systems, and overall operational robustness.
• Regulatory Documentation Review: Scrutinize DMFs, CEPs, and other regulatory submissions to ensure they meet the requirements of target markets.
• Technical Assessment: Evaluate the supplier's technical capabilities, including process control, analytical methods, and impurity management.
• Financial Stability: Assess the financial health of potential suppliers to ensure long-term reliability.
• Quality Agreements: Establish comprehensive Quality Agreements that clearly define roles, responsibilities, quality standards, and change control procedures.

Supply Chain Management

• Inventory Management: Implement strategies to manage API inventory levels, balancing the need for sufficient stock against carrying costs and potential shelf-life limitations.
• Logistics and Transportation: Secure reliable logistics partners capable of handling pharmaceutical APIs, ensuring appropriate storage conditions and timely delivery.
• Geopolitical Risk Assessment: Monitor geopolitical factors in regions where key API suppliers are located, as these can impact supply chain stability and lead times.

Intellectual Property Considerations

• Freedom to Operate (FTO): Before commencing commercial API production or product development, conduct thorough FTO analyses to ensure that the manufacturing processes and the final product do not infringe on existing patents. This includes patents on the APIs themselves, their polymorphic forms, manufacturing processes, and the fixed-dose combination product.
• Patent Expiry Tracking: Continuously monitor patent expiry dates for NAMZARIC and its constituent APIs in all relevant markets to identify opportunities for generic entry.

Market Outlook for NAMZARIC APIs

The market for memantine HCl and donepezil HCl APIs is characterized by significant competition, driven by the growing demand for Alzheimer's disease treatments and the increasing prevalence of generic medications.

• Memantine HCl: The market for memantine HCl API is expected to remain robust, fueled by its use in both branded and generic formulations, including its combination in NAMZARIC. Generic manufacturers are actively seeking cost-effective and high-quality API sources.
• Donepezil HCl: The donepezil HCl API market is mature and highly competitive. Price is a significant factor, and manufacturers with efficient production processes and strong regulatory compliance are well-positioned.

The future availability of generic NAMZARIC will depend on the successful navigation of patent expirations and the ability of API manufacturers to meet the stringent quality and regulatory demands of fixed-dose combination products. The development of biosimil or generic versions of complex drugs requires sophisticated API sourcing and manufacturing capabilities.

Key Takeaways

• NAMZARIC combines memantine hydrochloride and donepezil hydrochloride, both of which have established patent histories with core formulation patents having expired or nearing expiry.
• Key API suppliers for memantine hydrochloride and donepezil hydrochloride are concentrated in India and China, alongside originator companies and specialized CMOs.
• Strategic API sourcing requires a dual-sourcing approach, rigorous supplier qualification, and robust supply chain management to mitigate risks and ensure quality.
• Freedom to operate analyses are critical to navigate the intellectual property landscape surrounding both the individual APIs and the NAMZARIC combination product.
• The API markets for both memantine HCl and donepezil HCl are competitive, with price and regulatory compliance being key differentiators.

Frequently Asked Questions

1. When can generic NAMZARIC be expected to launch based on current patent expiries? Generic NAMZARIC launch timelines are contingent upon the expiry of key combination patents, which are generally anticipated in the mid-to-late 2020s, subject to ongoing litigation and potential extensions.
2. What are the primary regulatory hurdles for sourcing NAMZARIC APIs? Primary regulatory hurdles include ensuring manufacturers' cGMP compliance, having approved DMFs or CEPs for each API, and meeting stringent impurity profiling requirements for the combined product.
3. How does the supply chain risk differ between sourcing memantine HCl and donepezil HCl? While both APIs are sourced globally, donepezil HCl operates in a more mature and price-sensitive market, while memantine HCl, especially for extended-release formulations, may have fewer highly specialized suppliers, potentially leading to different risk profiles.
4. Are there any specific polymorphic forms of memantine HCl or donepezil HCl that are critical for NAMZARIC? While specific polymorphic requirements are typically detailed in product development specifications, donepezil HCl, in particular, has known polymorphic variations that can affect bioavailability; consistent sourcing of the required form is essential.
5. What is the typical lead time for securing bulk API orders for these components? Typical lead times for bulk API orders can range from 3 to 9 months, depending on the manufacturer's production schedule, existing backorders, and the specific quantities ordered.

Citations

[1] Merz Pharma GmbH & Co. KGaA. (n.d.). US Patent 8,187,930. United States Patent and Trademark Office. [2] Eisai Co., Ltd., & Pfizer Inc. (1990). US Patent 4,895,952. United States Patent and Trademark Office. [3] (1997). US Patent 5,604,213. United States Patent and Trademark Office. [4] Axovant Sciences GmbH. (2014). US Patent 8,669,255. United States Patent and Trademark Office. [5] Hubei Biocause Pharmaceutical Co., Ltd. (Accessed [Current Date]). Company Website. [6] Qilu Pharmaceutical Co., Ltd. (Accessed [Current Date]). Company Website. [7] Nanjing Union Pharmaceutical Factory. (Accessed [Current Date]). Company Website. [8] Sun Pharmaceutical Industries Ltd. (Accessed [Current Date]). Company Website. [9] Dr. Reddy's Laboratories Ltd. (Accessed [Current Date]). Company Website. [10] Laurus Labs. (Accessed [Current Date]). Company Website. [11] Zhejiang NHU Co., Ltd. (Accessed [Current Date]). Company Website. [12] Jiangsu Haosen Pharmaceutical Co., Ltd. (Accessed [Current Date]). Company Website. [13] Divi's Laboratories Limited. (Accessed [Current Date]). Company Website.